BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOLFree Report) in a research report report published on Monday morning. The brokerage issued a sell rating on the medical technology company’s stock.

Several other equities analysts have also recently issued reports on BIOL. Benchmark reaffirmed a “speculative buy” rating and set a $0.40 price objective on shares of BIOLASE in a report on Wednesday, October 2nd. Ascendiant Capital Markets decreased their price objective on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd.

View Our Latest Report on BIOLASE

BIOLASE Stock Performance

BIOLASE stock opened at $0.01 on Monday. BIOLASE has a one year low of $0.02 and a one year high of $1.94. The company has a market cap of $400,884.00, a P/E ratio of 0.00 and a beta of 0.67. The business has a fifty day moving average of $0.01 and a two-hundred day moving average of $0.04.

About BIOLASE

(Get Free Report)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.

Featured Stories

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.